AstraZeneca acquires rights to potential COPD treatment in deal valued at up to $402M
November 28, 2022 at 10:54 AM EST
The global licensing deal also includes exclusive rights for other undisclosed inflammatory and respiratory diseases.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|